Study Results on Reported Suspected Cases of Skin Reactions with Temporal Association to the Shingrix Vaccination against Herpes Zoster and Postherpetic Neuralgia

The recombinant subunit vaccine Shingrix has been approved in Europe since 2018 for the prevention of herpes zoster and postherpetic neuralgia in people aged 50 years and over. After its introduction into the German market in May 2018, the Paul-Ehrlich-Institut received reports of suspected cases of herpes zoster and pronounced skin reactions in close temporal association to Shingrix vaccination. The following article presents the results of an observational study in which a series of such suspected cases were investigated virologically and dermatologically.